Regulating Pre-implantation Genetic Diagnosis


Book Description

The successful achievement of pregnancies following pre-implantation genetic diagnosis (PGD) was first reported in April 1990. The technology is often used for patients who are at substantial risk of conceiving a pregnancy affected by a known genetic disorder, however from this technology other more controversial uses have arisen such as HLA typing to save the life of a sibling, gender selection for social reasons, the prevention of late onset diseases, or the prevention of diseases which may be genetically predisposed to developing such as breast cancer. The technology surrounding PGD is constantly developing, giving rise to new and unexpected consequences that create fresh ethical and legal dilemmas. Featuring internationally recognized experts in the field, this book critically explores the regulation of PGD and the broader legal and ethical issues associated with it. It looks at the regulatory situation in a number of jurisdictions including New Zealand, Australia and the United Kingdom, but it also explores a number of themes of wide significance including a historical consideration of PGD and its part in the creation of the "genetic embryo" as a political tool, the over regulation of PGD and the ethical difficulties in handling additional unexpected medical information yielded by new technologies. This book will be of particular interest to academics and students of law, medicine and ethics.




Comparative Legal Frameworks for Pre-Implantation Embryonic Genetic Interventions


Book Description

This book discusses the possibilities for the use of ​international human rights law ​(and specifically, international biomedical laws related to the protection of human rights and the human genome) to provide a guiding framework for the future regulation of genetic modifications applied to human embryos and other precursor materials, when these are made with the aim of implanting a genetically altered embryo in a woman. The significance and timeliness of the work derives from the recent availability of CRISPR/​Cas9 and other gene editing tools, and from lacunae in international law regarding the legality of embryo modification with these tools and appropriate governance structures for the oversight of resulting practices. The emergence of ​improved genome editing tools like CRISPR/Cas9, holds the promise of eradicating genetic diseases in the near future. But its possible future applications with Pre-Implantation Genetic Diagnosis (PGD) raises a plethora of legal and ethical concerns about "remaking" future human beings. The work aims to address an urgent call, to embed these rising concerns about biomedical advancements into the fundamental tailoring of legal systems. Suitable regulatory approaches, coupled with careful reflection of global biomedical laws and individual constitutional systems must be explored. The Book analyzes the impact of reproductive biomedical technologies on the legal and ethical dimensions of regulatory frameworks in selected constitutional systems like the US, the UK, Australia, Malaysia and Thailand. Employing a comparative law methodology, the work reveals a dynamic intersection between legal cultures, socio-philosophical reasoning and the development of a human rights-based framework in bio-political studies. Navigating towards a truly internationalized biomedical approach to emerging technologies, it presents an understanding why a renegotiation and reinvigoration of a contemporary and "new" universal shared values system in the ​international human rights discourse is now necessary.




Regulating Preimplantation Genetic Diagnosis in the United States


Book Description

Reproductive technology allows us to test embryos' genes before deciding whether to transfer them to a woman's uterus. Embryo selection raises many ethical questions but is virtually unregulated in the United States. This comprehensive study considers the ethical, medical, political, and economic aspects of developing appropriate regulation.




Revisiting the Regulation of Human Fertilisation and Embryology


Book Description

The Human Fertilisation and Embryology Act 2008 was a major update to the UK’s laws on the use and regulation of reproductive technology and assisted reproduction. Since the enactment of the new law, the sector’s regulatory body, the Human Fertilisation and Embryology Authority (HFEA), has also consulted on various related topics including barriers to egg and sperm donation in the UK, multiple births/single embryo transfer and using IVF technology to prevent mitochondrial disease. This book critically considers recent developments in human fertilisation legislation, asking whether the 2008 Act has achieved its stated aim of being fit for purpose. Bringing together a range of international experts, the book evaluates the fresh risks and challenges emerging from both established and existing technologies and techniques in the field of human fertilisation and embryology, as well as offering valuable insights into the social and regulatory challenges that lie ahead. Key topics include problems with DIY assisted conception; the lack of reform in respect of the regulation of surrogacy arrangements; and mitochondrial DNA transfer. As a review of the status of assisted reproduction legislation, this book will be of great use and interest to students, researchers and practitioners in medical law, bioethics, medicine and child welfare.




Born and Made


Book Description

'Born and Made' examines the case of preimplantation genetic diagnosis (PGD), the procedure used to prevent serious genetic disease by embryo selection, and the so-called 'designer baby' method. It shows that far from being a runaway technology, the regulation of PGD provides an example of precaution and restraint.




The Ethics of Genetics in Human Procreation


Book Description

This title was first published in 2000: This third volume of proceedings of the European Network for Biomedical Ethics focuses on the ethical issues surrounding the debates on reproductive medicine and genetics in human procreation. Central issues include procreation and parenthood, moral protection of the human embryo and foetus, autonomy and recognition, social implications, moral reasoning in applied ethics, legal regulations of assisted procreation, genetic diagnosis and gene therapy. The legal regulation paper evaluates the central laws and guidelines of European countries.




Human Embryos and Preimplantation Genetic Technologies


Book Description

Human Embryos and Preimplantation Genetic Technologies: Ethical, Social, and Public Policy Aspects presents the first holistic analysis of PGD and PGS as it is practiced and regulated worldwide. In addition to scientific and technical aspects, the book provides perspectives on the ethical, legal, religious, policy and social implications of global assisted reproduction technologies, including in Africa, Asia, Europe, North and South America, and Australia. Chapters cover history, ethics, feminism, family dynamics, psychological and interpersonal factors, the current state of PGD and PGS in 20 different sovereign nations and religious communities, and provide an analysis of public policy concerns and future directions. Provides an in-depth discussion of PGD and PGS as practiced and regulated worldwide Offers an accessible resource for researchers, medical professionals, patients, regulators and policymakers seeking expert opinions on PGS and PGD Contains chapters contributed by international clinicians, researchers and thought leaders in the field of assisted reproductive technology




Preimplantation Genetic Diagnosis


Book Description

Preimplantation genetic diagnosis (PGD) constitutes one of the most significant medical innovations of the last two decades in the area of assisted reproductive technology. The information derived from the genetic analysis of cells aspirated from an embryo created by in vitro fertilisation (IVF) may be used for diverse purposes, all of which may influence the decision as to which embryos should be implanted, and which discarded. With the introduction of the Human Assisted Reproductive Technology (HART) Act 2004, the performance of PGD is now subject to legislative and regulatory restraint. The purpose of this report is to consider extensions to the current scope of permissible PGD in New Zealand, and to determine the effect of the HART Act 2004 provisions on decision-making in this area. In view of developments in science and in other jurisdictions, it is likely that there will be a demand to extend the current ambit of the regulatory framework. Extending, or refusing to extend the current parameters for PGD will require a clear articulation of how the principles declared in the HART Act 2004 which govern decision-making in this area are to be applied. This report examines the conducting of PGD in areas which would broaden the existing regulatory scheme. In the following section an analysis of the HART Act 2004, and in particular the purposes and principles of the Act, will be undertaken to provide a foundation for the substantive examination of expansions to PGD in the following sections. The expansions discussed in sections 3 and 4 involve human leukocyte antigen (HLA) tissue typing and negative selection of healthy carrier embryos, respectively. In a field of rapid scientific progress, the last section in this report provides an update regarding the most recent development in the field of PGD: preimplantation genetic haplotyping (PGH).




Choosing between Possible Lives


Book Description

This article critically appraises the current legal scope of the principal applications of preimplantation genetic diagnosis (PGD). This relatively new technique, which is available to some parents undergoing in vitro fertilization (IVF) treatment, aims to ensure that a child is not born with a seemingly undesirable genetic condition. The question addressed here is whether there should be serious reasons to test for genetic conditions in embryos in order to be able to select between them. The Human Fertilisation and Embryology Authority and the Human Genetics Commission have decided that there should be such reasons by broadly aligning the criteria for PGD with those for selective abortion. This stance is critically explored, as are its implications for the possible use of PGD to select either against or for marginal features or for significant traits. The government is currently reviewing the legal scope and regulation of PGD.